{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)","groups":[{"description":"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.\n\nMAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.\n\nHyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy\n\nStereotactic radiosurgery: Undergo stereotactic radiosurgery\n\nAlisertib: Given PO\n\nQuality-of-life assessment: Ancillary studies","id":"OG000","title":"Alisertib, Fractionated Stereotactic Radiosurgery"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Number of Participants With Complete or Partial Response","type":"SECONDARY","unitOfMeasure":"Participants"}